Medicines Discovery Catapult (MDC) today announces the reappointment of Prof. Chris Molloy as CEO from January 2022.
Following an extensive international search, the MDC Board unanimously came to the decision that Chris Molloy was the best candidate to continue leading MDC into its next phase of ambitious growth.
In its first 5 years, with Chris at the helm, MDC has delivered tangible R&D impacts across the UK’s medicines discovery sector and has also spearheaded the creation of the UK Lighthouse Lab network.
MDC’s bright and ambitious future is one of growth, development and expanded impact. In his role as CEO Chris will lead the development and delivery of a plan that builds on MDC’s successes to date, supports the UK’s Life Sciences Sector vision for excellence in R&D and creates a nurturing business environment for UK companies and investors.
Under Chris’ stewardship MDC will continue to reshape UK Medicines Discovery by taking more risk, helping more companies, and securing more money for innovation.
Prof. Chris Molloy said:
“MDC’s people have the ambition to do more, help more and be an agent of positive change. I am really looking forward to the next phase of growth and development for MDC and the Catapult model.”
Dr. Robin Brown, Chairman, Medicines Discovery Catapult, said:
“The board are delighted to reconfirm Chris as CEO of MDC. Chris has overseen the successful growth of the organisation and has played a significant role in utilising MDC’s expertise to make nationally important contributions to COVID-19 testing and lateral flow test manufacturing. The future is bright for MDC and we have an ambitious plan for our further growth that is sure to flourish in the hands of Chris and his team.”